Article | January 28, 2022

Is In-House Manufacturing The Key To Delivering The World's First Diabetes Vaccine?

Source: Cytiva

Worldwide, nearly 422 million people have diabetes, with 1.6 million deaths directly attributed to this disease each year, according to the World Health Organization.1 This causes an overwhelming burden that is placed on patients, in terms of their health and the cost of medication. Organizations like the CDC and American Diabetes Association spend billions of dollars on diabetes prevention and management. However, without therapies that can target the metabolic abnormalities in diabetic patients, preventing the body’s attack on insulin and even improving its ability to create it, these investments may only become a drop in the ocean.

Diamyd Medical, a Swedish biotech company dedicated to preventing, treating, and curing autoimmune diabetes, is making significant clinical progress with its diabetes vaccine, Diamyd®. Delivering this product to market requires a robust manufacturing process and a facility to consistently execute it. With the increasing constraints on today’s supply chain from the COVID-19 pandemic, drug companies like Diamyd Medical must secure strategies that can ensure product delivery despite the challenges.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.

Subscribe to Bioprocess Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Bioprocess Online